TITLE

Pneumonia Hospitalizations Among Young Children Before and After Introduction of Pneumococcal Conjugate Vaccine -- United States, 1997-2006

AUTHOR(S)
Grijalva, J. P.; Griffin, M. R.; Nuorti, J. P.; Walter, N. D.
PUB. DATE
January 2009
SOURCE
MMWR: Morbidity & Mortality Weekly Report;1/16/2009, Vol. 58 Issue 1, p1
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article provides information on all-cause pneumonia hospitalizations among children before and after introduction of pneumococcal conjugate vaccine (PCV7). It says that the rate for all-cause pneumonia among children aged 2-4 years did not change after PCV7 licensure and has remained stable. A total of 74,559 children aged <2 years were hospitalized in 2005 in the U.S. for all-cause pneumonia, and 67,430 were hospitalized in 2006.
ACCESSION #
36268360

 

Related Articles

  • Pneumococcal Vaccine: The Evidence Mounts. LaForce, Marc // Annals of Internal Medicine;Jan86, Vol. 104 Issue 1, p110 

    Editorial. Explores the efficacy of pneumococcal pneumonia vaccine in the U.S. Results of field trials; Approach in measuring vaccine efficacy; Recommendations on the use of pneumococcal vaccine.

  • Pneumonia Vaccine--Don't Leave Home Without It. Brown, Edwin W. // Medical Update;Mar99, Vol. 22 Issue 9, p4 

    Focuses on pneumonia vaccine in the United States. Types of people eligible for the vaccine; Reasons for people's reluctance to be vaccinated.

  • Flag charts to assure vaccination against pneumococcal pneumonia.  // Geriatrics;Nov97, Vol. 52 Issue 11, p17 

    Focuses on flagging patient's chart to assure vaccination against pneuomococcal pneumonia. Recommendations of Chatrchai Watanakunakorn, director of infectious disease at Saint Elizabeth Health Center in Youngstown, Ohio about pneumococcal vaccine; Results of Watanakunakorn's study on patients...

  • Clinical efficacy of anti-pneumococcal vaccination in patients with COPD. Alfageme, I.; Vazquez, R.; Reyes, N.; Muñoz, J.; Fernández, A.; Hernandez, M.; Merino, M.; Perez, J.; Lima, J. // Thorax;Mar2006, Vol. 61 Issue 3, p189 

    Background: A study was undertaken to evaluate the clinical efficacy of the 23-valent pneumococcal polysaccharide vaccine (PPY) in immunocompetent patients with chronic obstructive pulmonary disease (COPD). Methods: A randomised controlled trial was carried out in 596 patients with COPD of mean...

  • Older adults are still not receiving pneumococcal vaccine.  // Modern Medicine;Jul95, Vol. 63 Issue 7, p35 

    Reports on the low vaccination rates for pneumococcal pneumonia due to incomplete vaccination of older adults in the United States based on a survey by Mark A. Miller presented at the International Conference of the American Lung Association and American Thoracic Society on May 20-24, 1995. ...

  • Latest developments with pneumococcal vaccines.  // Pulse;10/14/2002, Vol. 62 Issue 39, p44 

    Presents developments on pneumococcal vaccines for invasive pneumococcal disease. Physiological effects of pneumococcal disease; Response of children's immune system to pneumococcal polysaccharide; Importance of vaccination as strategy in prevention of diseases.

  • Will the 7-valent pneumococcal vaccine have a similar impact on all invasive pneumococcal infections in children in Germany as in the Kaiser Permanente Trial? von Kries, Rüdiger; Hermann, Monika; Al-Lahham, Adnan; Siedler, Anette; Reinert, René // European Journal of Pediatrics. Supplement;2002, Vol. 161, pS140 

    A 7-valent pneumococcal conjugate (7-vPc) vaccine was shown to be highly effective in California preventing 89.1% of all invasive pneumococcal infections (IPI) regardless of serotype. There is concern whether a similar effectiveness will be attained in Germany where 52% of all IPI in children <...

  • Safety and efficacy of the seven-valent pneumococcal conjugate vaccine: evidence from Northern California. Black, Steven; Shinefield, Henry // European Journal of Pediatrics. Supplement;2002, Vol. 161, pS127 

    Pneumococcal disease remains a significant cause of morbidity among young children. A large-scale efficacy trial in the Northern California Kaiser Permanente system (the KP trial) demonstrated that a sevenvalent conjugate vaccine (PCV) is safe and immunogenic in young children and effective in...

  • Pneumonia vaccine saves lives.  // New York Amsterdam News;10/09/97, Vol. 88 Issue 41, p18 

    Presents information on a vaccine for pneumococcal pneumonia, an illness that claims thousands of lives annually. Comments from Daniel M. Musher, an infectious disease expert at Houston's Baylor College of Medicine and Veterans Affairs Medical Center; How the vaccine will help patients.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics